Shunhei Yamashina

Dr. Shunhei Yamashina

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2014 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
YFYuka Fukuo
Yuka Fukuo
SYShunhei Yamashina
Shunhei Yamashina
HSHiroshi Sonoue
Hiroshi Sonoue
AAAtsushi Arakawa
Atsushi Arakawa
ENEisuke Nakadera
Eisuke Nakadera
SWSumio Watanabe
Sumio Watanabe

17 September 2009 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TMTomokazu Mizui
Tomokazu Mizui
SYShunhei Yamashina
Shunhei Yamashina
ITIsei Tanida
Isei Tanida
YTYoshiyuki Takei
Yoshiyuki Takei
TUTakashi Ueno
Takashi Ueno
SWSumio Watanabe
Sumio Watanabe

29 November 2011 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
YIYuki Igusa
Yuki Igusa
SYShunhei Yamashina
Shunhei Yamashina
KIKousuke Izumi
Kousuke Izumi
YIYoshihiro Inami
Yoshihiro Inami
HFHiroo Fukada
Hiroo Fukada
SWSumio Watanabe
Sumio Watanabe

23 February 2018 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
HFHirofumi Fukushima
Hirofumi Fukushima
SYShunhei Yamashina
Shunhei Yamashina
AAAtsushi Arakawa
Atsushi Arakawa
GTGentaro Taniguchi
Gentaro Taniguchi
TATomonori Aoyama
Tomonori Aoyama
SWSumio Watanabe
Sumio Watanabe

1 January 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ENEisuke Nakadera
Eisuke Nakadera
SYShunhei Yamashina
Shunhei Yamashina
KIKousuke Izumi
Kousuke Izumi
YIYoshihiro Inami
Yoshihiro Inami
TSToshifumi Sato
Toshifumi Sato
SWSumio Watanabe
Sumio Watanabe

1 November 2019 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Open access
PDF file
RKRyuta Kitagawa
Ryuta Kitagawa
KKKazuyoshi Kon
Kazuyoshi Kon
Akira UchiyamaAkira Uchiyama
Akira Uchiyama
KAKumiko Arai
Kumiko Arai
SYShunhei Yamashina
Shunhei Yamashina
KIKenichi Ikejima
Kenichi Ikejima
Exacerbation of alcoholic hepatitis (AH) with comorbid metabolic syndrome is an emerging clinical problem, where microbiota plays a profound role in the pathogenesis. Here, we investigated the effect of rifaximin (RFX) on liver injury following chronic-binge ethanol (EtOH) administration in KK-Ay mice, a rodent model of metabolic syndrome. Female, 8-wk-old KK-Ay mice were fed Lieber–DeCarli diet (5% EtOH) for 10 days, following a single EtOH gavage (4 g/kg body wt). Some mice were given RFX (0.1 g/L, in liquid diet) orally. Small intestinal contents were collected from mice without binge. Intestinal microbiota was quantified using aerobic and anaerobic culturing techniques and further analyzed by 16S rRNA sequencing in detail. EtOH feeding/binge caused hepatic steatosis, oxidative stress, and induction of inflammatory cytokines in KK-Ay mice, which were markedly prevented by RFX treatment. Hepatic mRNA levels for cluster of differentiation 14, Toll-like receptor (TLR) 4, TLR2, and NADPH oxidase 2 were increased following EtOH feeding/binge, and administration of RFX completely suppressed their increase. The net amount of small intestinal bacteria was increased over threefold after chronic EtOH feeding as expected; however, RFX did not prevent this net increase. Intriguingly, the profile of small intestinal microbiota was dramatically changed following EtOH feeding in the order level, where the Erysipelotrichales predominated in the relative abundance. In sharp contrast, RFX drastically blunted the EtOH-induced increases in the Erysipelotrichales almost completely, with increased proportion of the Bacteroidales. In conclusion, RFX prevents AH through modulation of small intestinal microbiota/innate immune responses in obese KK-Ay mice. NEW & NOTEWORTHY Here we demonstrated that rifaximin (RFX) prevents chronic-binge ethanol (EtOH)-induced steatohepatitis in KK-Ay mice. Chronic EtOH feeding caused small intestinal bacterial overgrowth, with drastic alteration in the microbiota profile predominating the order Erysipelotrichales. RFX minimized this EtOH induction in Erysipelotrichales with substitutive increases in Bacteroidales. RFX also prevented EtOH-induced increases in portal lipopolysaccharide, and hepatic cluster of differentiation 14, toll-like receptor (TLR) 2, and TLR4 mRNA levels, suggesting the potential involvement of microbiota-related innate immune responses.